Leading biotech companies and healthcare firms lost billions in market value over 10 days in April when conversations in Washington turned to Medicare for All, threatening their outlooks for growth and capital. The rhetoric injected a major dose of uncertainty into the market, analysts said, implying huge pricing cuts for pharma and biotech firms, such…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
